Abstract
As earlier detection of prostate cancer increases because of prostate-specific antigen (PSA) testing, appropriate use for watchful waiting warrants re-evaluation. We have drawn together the significant watchful waiting literature and used it to evaluate the use of watchful waiting in the PSA era. We conducted literature searches for studies examining outcomes of watchful waiting and examined new literature emerging about the use of PSA for the follow-up of watchful waiting patients. Watchful waiting has the potential to play an increasingly important role in prostate cancer as less advanced disease is detected and methods are refined for identifying low-risk patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ et al. High grade prostatic intraepithelial (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994; 8: 439–443.
Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J . Long term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626–631.
Albertsen PC, Hanley JA, Gleason DF, Barry MJ . Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 1008–1010.
Albertsen PC, Hanley JA, Fine J . 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095–2101.
Johansson JE, Adami HO, Andersson SO, Bergstrom R, Krusemo UB, Kraal W . Natural history of localized prostatic cancer. A population-based study in 223 untreated patients. Lancet 1989; 8642: 799–803.
Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB . High 10 year survival rate in patients with early, untreated prostatic cancer. JAMA 1992; 267: 2191–2196.
Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO . Fifteen year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277: 467–471.
Johansson JE, Andren O, Andersson SO, Dickman P, Holmberg L, Magnusson A et al. Natural history of early, localized prostate cancer. JAMA 2004; 291: 2713–2719.
Chodak GW, Thisted RA, Gerber GS, Johansson J, Adolfsson J, Jones GW et al. Results of conservative management of clinically localized prostate cancer. N Eng J Med 1994; 330: 242–248.
Gerber GS, Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996; 276: 615–619.
Holmberg L, Bill-Axelson A, Helgessen F, Sako JO, Folmerz P, Haggman M et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781–789.
Bill Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977–1984.
Wilt TJ, Brawer MK . The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology 1997; 11: 1133–1139.
Epstein JI, Walsh PC, Brendler CB . Radical prostatectomy for impalpable prostate cancer: the John Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 1994; 152: 1721–1729.
Klotz LH . Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 2004; 172: 48–60.
Klotz LH . Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005; 47: 16–21.
Klotz LH . Active surveillance with selective delayed intervention: walking the line between over treatment for indolent disease and under treatment for aggressive disease. Can J Urol 2005; 12 (Suppl): 53–57.
Epstein JI, Sanderson H, Carter HB, Scharfstein DO . Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005; 66: 356–360.
Carter CA, Donahue T, Sun L, Wu H, Mcleod DG, Amling C et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 2003; 21: 4001–4008.
Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP, Carrol PR et al. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol 2003; 170: 2279–2283.
Wu H, Sun L, Moul JW, Wu HY, Mcleod DG, Amling C et al. Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol 2004; 171: 111–116.
el-Geneidy M, Garzotto M, Panagiotou I, Hsieh YC, Mori M, Peters L et al. Delayed therapy with curative intent in a contemporary prostate cancer watchful waiting cohort. BJU Int 2004; 93: 501–505.
Acknowledgements
Katherine Warren supported by Midwest Urology Research Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chodak, G., Warren, K. Watchful waiting for prostate cancer: a review article. Prostate Cancer Prostatic Dis 9, 25–29 (2006). https://doi.org/10.1038/sj.pcan.4500857
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500857
Keywords
This article is cited by
-
Autophagy as a modulator and target in prostate cancer
Nature Reviews Urology (2014)